CY2016043I1 - Μεθοδος για τη θεραπευτικη αγωγη της πολλαπλης σκληρυνσης - Google Patents

Μεθοδος για τη θεραπευτικη αγωγη της πολλαπλης σκληρυνσης

Info

Publication number: CY2016043I1
Authority: CY; Cyprus
Prior art keywords: multiple sclerosis; therapeutic treatment; therapeutic; treatment; sclerosis
Prior art date: 2002-06-28

Application number

CY2016043C

Other languages

English (en)

Other versions

CY2016043I2 (el

Original Assignee

The Government Of The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services, National Institutes Of Health

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-06-28

Filing date

2016-12-09

Publication date

2017-04-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=30000962&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2016043(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-12-09 Application filed by The Government Of The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services, National Institutes Of Health filed Critical The Government Of The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services, National Institutes Of Health

2017-04-05 Publication of CY2016043I1 publication Critical patent/CY2016043I1/el

2017-04-05 Publication of CY2016043I2 publication Critical patent/CY2016043I2/el

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0033—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room
- A61B5/004—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part
- A61B5/0042—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part for the brain
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Immunology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Biophysics (AREA)
Neurology (AREA)
Radiology & Medical Imaging (AREA)
Physics & Mathematics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Surgery (AREA)
Medical Informatics (AREA)
Heart & Thoracic Surgery (AREA)
Pathology (AREA)
Microbiology (AREA)
Mycology (AREA)
Neurosurgery (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Endocrinology (AREA)
High Energy & Nuclear Physics (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Orthopedic Medicine & Surgery (AREA)

CY2016043C 2002-06-28 2016-12-09 Μεθοδος για τη θεραπευτικη αγωγη της πολλαπλης σκληρυνσης CY2016043I2 (el)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US39302102P	2002-06-28	2002-06-28
PCT/US2002/038290 WO2004002500A1 (en)	2002-06-28	2002-11-27	Method of treating autoimmune diseases with interferon-beta and il-2r antagonist
PCT/US2003/020428 WO2004002421A2 (en)	2002-06-28	2003-06-27	Method for the treatment of multiple sclerosis

Publications (2)

Publication Number	Publication Date
CY2016043I1 true CY2016043I1 (el)	2017-04-05
CY2016043I2 CY2016043I2 (el)	2017-04-05

Family

ID=30000962

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CY2016043C CY2016043I2 (el)	2002-06-28	2016-12-09	Μεθοδος για τη θεραπευτικη αγωγη της πολλαπλης σκληρυνσης
CY20171100999T CY1119389T1 (el)	2002-06-28	2017-09-21	Μεθοδος για τη θεραπευτικη αγωγη της πολλαπλης σκληρυνσης

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
CY20171100999T CY1119389T1 (el)	2002-06-28	2017-09-21	Μεθοδος για τη θεραπευτικη αγωγη της πολλαπλης σκληρυνσης

Country Status (15)

Country	Link
US (11)	US7575742B2 (el)
EP (3)	EP2314627B1 (el)
JP (8)	JP2005535636A (el)
AU (3)	AU2002368055B2 (el)
CA (3)	CA2490804C (el)
CY (2)	CY2016043I2 (el)
DK (2)	DK2314627T3 (el)
ES (2)	ES2637011T3 (el)
HK (1)	HK1249850A1 (el)
HU (2)	HUE036677T2 (el)
IL (2)	IL165973A (el)
LU (1)	LU93315I2 (el)
PT (2)	PT1539200E (el)
SI (2)	SI2314627T1 (el)
WO (2)	WO2004002500A1 (el)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR100884971B1 (ko) *	2001-04-26	2009-02-23	모션 테크놀로지즈 엘엘씨	연속 가변 변속기
WO2004002500A1 (en) *	2002-06-28	2004-01-08	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Method of treating autoimmune diseases with interferon-beta and il-2r antagonist
US20060134750A1 (en) *	2004-03-10	2006-06-22	Pepgen Corporation	Method of treatment using interferon-tau
CN101102739B (zh)	2005-01-12	2017-02-08	比奥根Ma公司	运输干扰素‑β的方法
US20080279819A1 (en) *	2005-02-15	2008-11-13	Adamas Pharmaceuticals, Inc.	Combinations Therapy for Treatment of Demyelinating Conditions
US8114630B2 (en)	2007-05-02	2012-02-14	Ambrx, Inc.	Modified interferon beta polypeptides and their uses
US20100055098A1 (en) *	2008-08-28	2010-03-04	Facet Biotech Corporation	Method for treating multiple sclerosis patients with anti-il2r antibodies
JP2012505257A (ja) *	2008-10-13	2012-03-01	バイオヴィスタ，インコーポレイテッド	多発性硬化症治療のための組成物および方法
WO2010068923A2 (en) *	2008-12-12	2010-06-17	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Agents that selectively inhibit cd25 on dendritic cells or t cells and their use
US20110053209A1 (en) *	2009-08-31	2011-03-03	Facet Biotech Corporation	Use of an immunoregulatory nk cell population for monitoring the efficacy of anti-il-2r antibodies in multiple sclerosis patients
WO2011127324A2 (en) *	2010-04-08	2011-10-13	JN Biosciences, LLC	Antibodies to cd122
ES2989085T3 (es)	2011-01-18	2024-11-25	Bioniz Therapeutics Inc	Composiciones para modular la actividad de citoquinas gamma-c
WO2013022972A1 (en)	2011-08-08	2013-02-14	Abbott Biotherapeutics Corporation	Methods of treating progressive forms of multiple sclerosis
US9959384B2 (en)	2013-12-10	2018-05-01	Bioniz, Llc	Methods of developing selective peptide antagonists
DK3359556T3 (en)	2015-10-09	2021-08-30	Bioniz Llc	Modulering af gamma-c-cytokinaktivitet
WO2018027195A1 (en)	2016-08-05	2018-02-08	Abbvie Biotherapeutics Inc.	Compositions containing reduced amounts of daclizumab acidic isoforms and methods for preparing the same
DE102017104088A1 (de) *	2017-02-28	2018-08-30	L&O Hunting Group GmbH	Integralschalldämpfer für einen Gewehrlauf
EP3976182A4 (en)	2019-05-03	2023-01-18	Bioniz, LLC	MODULATION OF THE EFFECTS OF GAMMA CYTOKINE SIGNALING FOR THE TREATMENT OF ALOPECIA AND ALOPECIA-ASSOCIATED DISORDERS
JP2022544169A (ja) *	2019-08-07	2022-10-17	エディフィス・ヘルス・インコーポレイテッド	心血管疾患の処置および予防

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5807715A (en)	1984-08-27	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4819150A (en)	1985-04-05	1989-04-04	Unisys Corporation	Array for simulating computer functions for large computer systems
US5336489A (en)	1985-09-05	1994-08-09	The Beth Israel Hospital Association	Treatment of allograft rejection with IL-2 receptor-specific cytotoxins
US5011684A (en) *	1985-09-05	1991-04-30	Beth Israel Hospital Association	Lysing or blocking unwanted cells with IL-2 receptor-specific binding substance
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
GB2188941B (en)	1986-04-14	1990-06-06	Bayer Ag	Monoclonal antibodies recognizing human interleukin-2-receptor
US6051405A (en) *	1986-09-24	2000-04-18	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Constructs encoding recombinant antibody-toxin fusion proteins
US5013548A (en)	1987-09-08	1991-05-07	Duke University	Production of antibodies to HIV
US5695927A (en)	1988-03-31	1997-12-09	The University Of Arizona, Department Of Internal Medicine, Section Of Hematology And Oncology	Monoclonal antibodies specific for HIV and the hybridomas for production thereof
FI895955A7 (fi)	1988-04-15	1989-12-13	Protein Design Labs Inc	Il-2-reseptorispesifisiä "kimeerisiä" vasta-aineita
DE3815472A1 (de) *	1988-05-06	1989-11-16	Centre Regional De Transfusion	Monoklonaler antikoerper und seine verwendung
US5152980A (en)	1988-05-19	1992-10-06	The Beth Israel Hospital Association	Induction of tolerance to a foreign antigen IL-2 receptor-binding substances
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
ATE139258T1 (de)	1990-01-12	1996-06-15	Cell Genesys Inc	Erzeugung xenogener antikörper
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
DK0585287T3 (da)	1990-07-10	2000-04-17	Cambridge Antibody Tech	Fremgangsmåde til fremstilling af specifikke bindingsparelementer
US5620686A (en)	1990-09-28	1997-04-15	British Technology Group Limited	Antigen-antibody conjugates
US5840496A (en) *	1990-10-09	1998-11-24	Chiron Corporation	Method for diagnosing endometrial cancer
FR2672291A1 (fr)	1991-01-31	1992-08-07	Inst Nat Sante Rech Med	Composition d'anticorps diriges contre le recepteur de l'interleukine-2 humaine ou animale.
GB9115010D0 (en)	1991-07-11	1991-08-28	Wellcome Found	Antibody
JPH05244982A (ja) *	1991-12-06	1993-09-24	Sumitomo Chem Co Ltd	擬人化ｂ−ｂ１０
EP0746609A4 (en)	1991-12-17	1997-12-17	Genpharm Int	NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
US5571507A (en)	1992-02-25	1996-11-05	Seragen, Inc.	Methods of treating diabetes
US5643756A (en)	1992-08-28	1997-07-01	The Public Health Research Institute Of The City Of New York, Inc.	Fusion glycoproteins
DE69428896T2 (de)	1993-05-07	2002-06-20	Akzo Nobel N.V., Arnheim/Arnhem	Hiv immunogene komplexe
JPH09501891A (ja)	1993-08-27	1997-02-25	ザピルスベリーコムパニー	機械的なガスフラッシュ装置
US5635597A (en)	1994-05-27	1997-06-03	Affymax Technologies, N.V.	Peptides that bind IL-2 receptors
DK0772619T4 (da)	1994-07-15	2011-02-21	Univ Iowa Res Found	Immunmodulatoriske oligonukleotider
US6096728A (en)	1996-02-09	2000-08-01	Amgen Inc.	Composition and method for treating inflammatory diseases
US6013256A (en)	1996-09-24	2000-01-11	Protein Design Labs, Inc.	Method of preventing acute rejection following solid organ transplantation
US6833135B1 (en) *	1997-08-06	2004-12-21	Laboratorio Medinfar Produtos Farmaceuticos, Lda.	DNA integration into “Mycobacterium spp.” genome by trans-complementation using a site-specific integration system
WO2000025816A1 (en)	1998-10-30	2000-05-11	The University Of Miami	Treatment of hepatitis c by administration of anti-il-2 receptor monoclonal antibody and an antiviral compound
US6346247B1 (en)	1999-10-28	2002-02-12	Promega Corporation	Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies
US6899869B2 (en) *	2000-04-25	2005-05-31	Tomoaki Hoshino	Method of preparing an animal model for interstitial pneumonia
CN1296386C (zh) *	2001-04-06	2007-01-24	布里斯托尔大学	Cd25结合分子在类固醇耐受型患者中的用途
WO2004002500A1 (en) *	2002-06-28	2004-01-08	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Method of treating autoimmune diseases with interferon-beta and il-2r antagonist
AU2003251633A1 (en)	2002-07-01	2004-01-19	The Government Of The United States Of America As Represented By The Secretary Of The Department Of	Il-21 as a regulator of immunoglobin production

2002
- 2002-11-27 WO PCT/US2002/038290 patent/WO2004002500A1/en not_active Ceased
- 2002-11-27 JP JP2004517494A patent/JP2005535636A/ja not_active Withdrawn
- 2002-11-27 CA CA2490804A patent/CA2490804C/en not_active Expired - Lifetime
- 2002-11-27 AU AU2002368055A patent/AU2002368055B2/en not_active Ceased
- 2002-11-27 US US10/519,311 patent/US7575742B2/en not_active Expired - Fee Related
2003
- 2003-06-27 WO PCT/US2003/020428 patent/WO2004002421A2/en not_active Ceased
- 2003-06-27 EP EP10182563.6A patent/EP2314627B1/en not_active Expired - Lifetime
- 2003-06-27 PT PT37621810T patent/PT1539200E/pt unknown
- 2003-06-27 CA CA2490186A patent/CA2490186C/en not_active Expired - Fee Related
- 2003-06-27 CA CA2844639A patent/CA2844639A1/en not_active Abandoned
- 2003-06-27 AU AU2003247813A patent/AU2003247813C1/en not_active Ceased
- 2003-06-27 EP EP03762181.0A patent/EP1539200B1/en not_active Expired - Lifetime
- 2003-06-27 SI SI200332543T patent/SI2314627T1/sl unknown
- 2003-06-27 PT PT101825636T patent/PT2314627T/pt unknown
- 2003-06-27 HU HUE10182563A patent/HUE036677T2/hu unknown
- 2003-06-27 ES ES10182563.6T patent/ES2637011T3/es not_active Expired - Lifetime
- 2003-06-27 ES ES03762181.0T patent/ES2474718T3/es not_active Expired - Lifetime
- 2003-06-27 SI SI200332375T patent/SI1539200T1/sl unknown
- 2003-06-27 EP EP17175522.6A patent/EP3269377A1/en not_active Withdrawn
- 2003-06-27 JP JP2004518039A patent/JP2006508039A/ja not_active Withdrawn
- 2003-06-27 DK DK10182563.6T patent/DK2314627T3/en active
- 2003-06-27 US US10/607,598 patent/US7258859B2/en not_active Expired - Lifetime
- 2003-06-27 DK DK03762181.0T patent/DK1539200T3/da active
2004
- 2004-12-23 IL IL165973A patent/IL165973A/en active IP Right Grant
2007
- 2007-07-13 US US11/827,876 patent/US8454965B2/en not_active Expired - Fee Related
2008
- 2008-09-04 AU AU2008212004A patent/AU2008212004B2/en not_active Ceased
2009
- 2009-03-10 US US12/401,543 patent/US8298525B2/en not_active Expired - Fee Related
- 2009-12-16 JP JP2009284862A patent/JP2010132660A/ja not_active Withdrawn
2011
- 2011-04-04 JP JP2011082497A patent/JP2011157378A/ja not_active Withdrawn
2012
- 2012-05-18 US US13/475,688 patent/US20130017152A1/en not_active Abandoned
- 2012-09-12 US US13/612,763 patent/US8636997B2/en not_active Expired - Fee Related
- 2012-09-28 JP JP2012217520A patent/JP2013032372A/ja not_active Withdrawn
2013
- 2013-04-17 JP JP2013086246A patent/JP2013139478A/ja active Pending
2014
- 2014-07-18 JP JP2014147314A patent/JP5905534B2/ja not_active Expired - Lifetime
- 2014-09-15 US US14/487,012 patent/US20150010477A1/en not_active Abandoned
2015
- 2015-07-06 US US14/792,432 patent/US20150337044A1/en not_active Abandoned
- 2015-10-06 IL IL241920A patent/IL241920A0/en unknown
2016
- 2016-02-22 JP JP2016030540A patent/JP2016145220A/ja not_active Withdrawn
- 2016-08-11 US US15/234,575 patent/US20170190779A1/en not_active Abandoned
- 2016-11-17 LU LU93315C patent/LU93315I2/fr unknown
- 2016-12-07 HU HUS1600050C patent/HUS1600050I1/hu unknown
- 2016-12-09 CY CY2016043C patent/CY2016043I2/el unknown
2017
- 2017-09-21 CY CY20171100999T patent/CY1119389T1/el unknown
2018
- 2018-04-18 US US15/956,458 patent/US20180237532A1/en not_active Abandoned
- 2018-07-17 HK HK18109281.9A patent/HK1249850A1/en unknown
- 2018-09-17 US US16/132,852 patent/US20190002575A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20040109859A1 (en)	2004-06-10
US7575742B2 (en)	2009-08-18
US20180237532A1 (en)	2018-08-23
JP2013032372A (ja)	2013-02-14
IL241920A0 (en)	2015-11-30
US8636997B2 (en)	2014-01-28
JP2010132660A (ja)	2010-06-17
PT1539200E (pt)	2014-08-25
SI1539200T1 (sl)	2014-09-30
WO2004002421A2 (en)	2004-01-08
JP5905534B2 (ja)	2016-04-20
JP2013139478A (ja)	2013-07-18
EP2314627A2 (en)	2011-04-27
JP2016145220A (ja)	2016-08-12
JP2014221813A (ja)	2014-11-27
EP1539200A2 (en)	2005-06-15
JP2006508039A (ja)	2006-03-09
US20050249704A1 (en)	2005-11-10
AU2003247813C1 (en)	2010-07-22
ES2637011T3 (es)	2017-10-10
EP1539200B1 (en)	2014-05-28
US20170190779A1 (en)	2017-07-06
WO2004002421A3 (en)	2004-09-02
US20150010477A1 (en)	2015-01-08
DK2314627T3 (en)	2017-10-23
US20130017152A1 (en)	2013-01-17
HUS1600050I1 (hu)	2017-06-28
CA2490186A1 (en)	2004-01-08
AU2008212004A1 (en)	2008-09-25
CY2016043I2 (el)	2017-04-05
US8454965B2 (en)	2013-06-04
HK1249850A1 (en)	2018-11-16
WO2004002500A1 (en)	2004-01-08
AU2003247813B2 (en)	2008-06-05
US20190002575A1 (en)	2019-01-03
LU93315I2 (fr)	2017-01-26
SI2314627T1 (sl)	2017-10-30
HUE036677T2 (hu)	2018-07-30
IL165973A (en)	2015-10-29
CA2844639A1 (en)	2004-01-08
JP2005535636A (ja)	2005-11-24
CA2490804C (en)	2016-12-06
AU2008212004B2 (en)	2010-10-21
US20150337044A1 (en)	2015-11-26
EP2314627B1 (en)	2017-07-26
US20090175823A1 (en)	2009-07-09
IL165973A0 (en)	2006-01-15
CA2490804A1 (en)	2004-01-08
DK1539200T3 (da)	2014-06-30
US8298525B2 (en)	2012-10-30
JP2011157378A (ja)	2011-08-18
CA2490186C (en)	2014-04-15
EP2314627A3 (en)	2011-05-11
ES2474718T3 (es)	2014-07-09
AU2002368055A1 (en)	2004-01-19
US20130095069A1 (en)	2013-04-18
HK1074769A1 (en)	2005-11-25
EP1539200A4 (en)	2007-11-07
CY1119389T1 (el)	2018-02-14
US20080038275A1 (en)	2008-02-14
EP3269377A1 (en)	2018-01-17
AU2003247813A1 (en)	2004-01-19
US7258859B2 (en)	2007-08-21
AU2002368055B2 (en)	2008-09-18
PT2314627T (pt)	2017-08-29

Publication	Publication Date	Title
CY2016043I2 (el)	2017-04-05	Μεθοδος για τη θεραπευτικη αγωγη της πολλαπλης σκληρυνσης
CY2013021I2 (el)	2025-07-04	Συνθεσεις για τη θεραπευτικη αγωγη γαστροεντερικων διαταραχων
NO20052914D0 (no)	2005-06-15	Terapeutiske forbindelser
EP1482962A4 (en)	2009-12-23	METHOD OF TREATING THIOREDOXIN-MEDIATED DISEASES (TRX)
CY2013039I1 (el)	2015-11-04	Φθοροϋποκατεστημενη ωμεγα-καρβοξυαρυλ διφαινυλ ουρια για τη θεραπεια και προληψη ασθενειων και καταστασεων
NO20053077D0 (no)	2005-06-23	Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
NO20044054L (no)	2004-11-24	Administrering av midler for behandling av betennelse
DK1944322T3 (da)	2015-06-22	Behandling af TNFalfa-relaterede sygdomme
NO20044402L (no)	2004-12-17	Kombinasjonsbehandling av kemokine-medierte sykdommer
DE60322451D1 (de)	2008-09-04	4-Tetrazolyl-4-Phenylpiperidinderivate zur Schmerzbehandlung
IS7691A (is)	2005-02-09	Lyfjasamsetningar til að meðhöndla æxli
EA200500098A1 (ru)	2005-08-25	Лекарственное средство и способ лечения патологического синдрома
NO20040353L (no)	2004-03-26	Ny terapeutsk metode
NO20045554L (no)	2004-12-20	Fremgangsmate for behandling av diabetes
EP1651237A4 (en)	2008-10-01	METHODS OF TREATING DERMATOLOGICAL DISORDERS
DK1553950T3 (da)	2007-10-15	Terapeutisk behandling
NO20050689L (no)	2005-03-21	Terapeutisk anvendelse
DE60229887D1 (de)	2008-12-24	Oberflächenbehandlungssystem
NO20033160D0 (no)	2003-07-10	Anordning for behandling av gravann
EP1511474A4 (en)	2008-02-20	PROCESSING PROCESS
EE00323U1 (et)	2002-10-15	Kohanaha töötlemise meetod
SE0104249D0 (sv)	2001-12-14	Method of treatment
AUPS218102A0 (en)	2002-06-06	Method for the treatment of multiple sclerosis
AUPS219602A0 (en)	2002-06-06	Method for the treatment of multiple sclerosis
AUPS216802A0 (en)	2002-06-06	Method for the treatment of multiple sclerosis